Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.

Current cancer drug targets - 1 Jan 2018

Mansouri Sepideh, Farahmand Leila, Teymourzadeh Azin, Majidzadeh-A Keivan

Abstract excerpt

BACKGROUND: Despite prolonged disease-free survival and overall survival rates in Estrogen Receptor (ER)-positive patients undergoing adjuvant treatment, Tamoxifen therapy tends to fail due to eventual acquisition of resistance. OBJECTIVE: Although numerous studies have emphasized the Role of Receptor Tyrosine Kinases (RTKs) in the development of Tamoxifen resistance, inadequate clinical evidence is available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Estrogen Antagonists

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hedgehog Proteins

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Share to Tamoxifen

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 28786348
DOI: 10.2174/1568009617666170808110820

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.PMID 28786348Read ↗

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goalsSemantic proximity Read ↗

Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.Semantic proximity Read ↗

Endocrine resistance in breast cancer--An overview and update.Semantic proximity Read ↗

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceSemantic proximity Read ↗

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read ↗

Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.Semantic proximity Read ↗

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Semantic proximity Read ↗

Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine ResistanceSemantic proximity Read ↗

Mechanisms of aromatase inhibitor resistance.Semantic proximity Read ↗

Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast CancerSemantic proximity Read ↗

Modulation of estrogen receptor alpha activity and expression during breast cancer progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.